- Global Pharma News & Resources

Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets

Hyloris’ Partner AFT Pharmaceuticals Signs Licensing Agreement with Aguettant for Maxigesic® IV in Eight European Markets


Footprint across Europe now extended to a total of 20 EU member states

Maxigesic® IV offers a non-opioid alternative in post-operative pain management


Liège, Belgium – 5 March 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to bringing innovative treatments that offer added value to underserved patient populations, today announces that its partner AFT Pharmaceuticals (“AFT”) has signed an exclusive licensing agreement with Aguettant for Maxigesic IV, a novel, dual mode-of-action non-opioid pain treatment delivered through intravenous (IV) infusion, in eight European markets.


The agreement with Aguettant means that Maxigesic IV is now licensed in 20 out of the 27 EU member states (including the major pharma markets in the EU: Germany, France, Italy, and Spain) as well as the UK.  Aguettant gains the exclusive rights to Maxigesic IV in the Nordics (Finland, Norway, Denmark, Sweden and Iceland), Spain, Portugal, and the Netherlands. AFT expects sales of Maxigesic IV in these territories to commence in early 2022.


The market for post-operative pain is growing rapidly and is forecasted to reach $553 million in 2028 across the five major markets in Europe (up from $178 million in 2019)[1].


Stijn Van Rompay, Chief Executive Officer of Hyloris, commented: We are very pleased that AFT has entered into a licensing agreement with Aguettant, a major player in injectable pharmaceutical specialities and a strong sales record in the hospital sector across the EU. This agreement extends Maxigesic IV’s footprint in Europe and significantly expands its addressable market. There is an increasing need for safer and more effective non-opioid pain treatments in the post-operative hospital setting and thanks to its unique, dual mode-of-action, Maxigesic IV has the potential to become a valuable pain treatment option without the side effects and risk of addiction associated with opioids.


Maxigesic IV is a novel, dual mode-of-action, non-opioid pain treatment for use post-operatively in hospitals when patients cannot take a medicine orally. It is a unique combination of 1000mg paracetamol with 300mg ibuprofen solution for infusion, thereby reducing both pain and inflammation. Results from a randomised, placebo-controlled Phase 3 trial demonstrated that Maxigesic IV was well-tolerated and had a faster onset of action, offered higher pain relief, and provided the potential to reduce the use of opioids compared to ibuprofen IV or acetaminophen IV alone in the same doses[2]. Further exposure studies have demonstrated the drug’s efficacy and safety in an expanded population group over a longer treatment period[3]. Hyloris and AFT signed a development collaboration agreement in 2012 for Maxigesic IV and AFT has now licensed the product to partners covering more than 90 countries. Maxigesic IV is protected by several granted and pending patent applications. Under the terms of the development collaboration agreement between Hyloris and AFT, Hyloris is eligible to receive a share on any product-related revenues, such as license fees, royalties, milestone payments, received by AFT.



For more information, please contact:

Hyloris Pharmaceuticals

Marieke Vermeersch

VP Investor Relations and Corporate Communications

M: +32 (0)479 490 603 

[1] DelveInsight Market Research Report (2020)

[2] Daniels et al, 2018, Clinical Therapeutics

[3] Maxigesic IV Phase 3 exposure study. Study ID No AFT-MXIV-11. NCT04005755. Results presently unpublished

Editor Details

Last Updated: 05-Mar-2021